U.S. Markets closed

Merck KGaA-Pfizer to terminate late-stage ovarian cancer treatment study

Dec 21 (Reuters) - Pfizer Inc and Merck KGaA said on Friday they were terminating a late-stage study for a drug to treat a form of ovarian cancer in previously untreated patients.

The results from the study showed the treatment would not achieve superiority in achieving main goal of progression-free survival. (Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Arun Koyyur)